immune thrombocytopeniaITPTPO receptors agonistsиммунная тромбоцитопенияИТПстимуляторы рецепторов тромбопоэтина1.1. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–93.Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–93.2.2. Olsson B., Andersson P.O., Jernas M. et al. T-cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9(9):1123–4.Olsson B., Andersson P.O., Jernas M. et al. T-cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9(9):1123–4.3.3. McMillan R., Wang L., Tomer A., Nichol J., Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103(4):1364–9.McMillan R., Wang L., Tomer A., Nichol J., Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103(4):1364–9.4.4. Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia Blood 2010;115(2):168–186.Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia Blood 2010;115(2):168–186.5.5. Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess longterm platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623–34.Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess longterm platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623–34.6.6. Rodeghiero F., Besalduch J., Michel M. et al. Treatment practices in adults with chronic immune thrombocytopenia â a European perspective. European Journal of Haematology 2010;84(2):160–8.Rodeghiero F., Besalduch J., Michel M. et al. Treatment practices in adults with chronic immune thrombocytopenia â a European perspective. European Journal of Haematology 2010;84(2):160–8.7.7. Schwartz P.E., Sterioff S., Mucha P. et al. Postsplenectomy sepsis and mortality in adults. Journal of the American Medical Association 1982;248(18):2279–83.Schwartz P.E., Sterioff S., Mucha P. et al. Postsplenectomy sepsis and mortality in adults. Journal of the American Medical Association 1982;248(18):2279–83.8.8. Fontana V., Jy W., Ahn E.R. et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008;122(5):599–603.Fontana V., Jy W., Ahn E.R. et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008;122(5):599–603.9.9 Jaïs X., Ioos V., Jardim C. et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005;60:1031–4.Jaïs X., Ioos V., Jardim C. et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005;60:1031–4.10.10. Verlin M., Laros R.K., Penner J.A. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol 1976;1(1):97–104.Verlin M., Laros R.K., Penner J.A. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol 1976;1(1):97–104.11.11. Quiquandon I., Fenaux P., Caulier M.T. et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990 Feb;74(2):223–8.Quiquandon I., Fenaux P., Caulier M.T. et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990 Feb;74(2):223–8.12.12. Provan D., Moss A.J., Newland A.C., Bussel J.B. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006;81(1):19–25.Provan D., Moss A.J., Newland A.C., Bussel J.B. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006;81(1):19–25.13.13. Maloisel F., Andres E., Zimmer J. et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004;116(9):590–4.Maloisel F., Andres E., Zimmer J. et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004;116(9):590–4.14.14. Portielje J., Westendorp R., Kluin-Nelemans H. et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54.Portielje J., Westendorp R., Kluin-Nelemans H. et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54.15.15. Stasi R., Stipa E., Forte V., Meo P., Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99(10):3872–3.Stasi R., Stipa E., Forte V., Meo P., Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99(10):3872–3.16.16. Arnold D.M., Dentali F., Crowther M.A. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146(1):25–33.Arnold D.M., Dentali F., Crowther M.A. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146(1):25–33.17.17. Patel V.L., Mahévas M., Stasi R. Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP) Absracts of 52nd ASH Annual Meeting Orlando, Abstr.72.Patel V.L., Mahévas M., Stasi R. Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP) Absracts of 52nd ASH Annual Meeting Orlando, Abstr.72.18.18. Fianchi L., Rossi E., Murri R. et al. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 2007;86(3):225–6.Fianchi L., Rossi E., Murri R. et al. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 2007;86(3):225–6.19.19. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995;74(1):521–5.Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995;74(1):521–5.20.20. Nichol J.L. Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. Stem Cells 1998;16(Suppl 2):165–75.Nichol J.L. Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. Stem Cells 1998;16(Suppl 2):165–75.21.21. Fielder P.J., Gurney A.L., Stefanich E., Marian M., Moore M.W., Carver-Moore K., de Sauvage F.J. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1998;92(6):2189–91.Fielder P.J., Gurney A.L., Stefanich E., Marian M., Moore M.W., Carver-Moore K., de Sauvage F.J. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1998;92(6):2189–91.22.22. Mignotte V., Vigon I., Boucher de Crevecoeur E. et al. Structure and transcription of the human c-mpl gene (MPL). Genomics 1994;20:5–12.Mignotte V., Vigon I., Boucher de Crevecoeur E. et al. Structure and transcription of the human c-mpl gene (MPL). Genomics 1994;20:5–12.23.23. Bartley T.D., Bogenberger J., Hunt P. et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 1994;77:1117–24.Bartley T.D., Bogenberger J., Hunt P. et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 1994;77:1117–24.24.24. Li J., Yang C., Xia Y. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241–8.Li J., Yang C., Xia Y. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241–8.25.25. Bussel J.B., Kuter D.J., George J.N. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672–81.Bussel J.B., Kuter D.J., George J.N. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672–81.26.26. Bussel J.B., Cheng G., Saleh M.N. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357(22):2237–47.Bussel J.B., Cheng G., Saleh M.N. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357(22):2237–47.27.27. Kuter D.J., Bussel J.B., Lyons R.M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008;371(9610):395–403.Kuter D.J., Bussel J.B., Lyons R.M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008;371(9610):395–403.28.28. Cheng G., Saleh M.N., Marcher C. et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393–402.Cheng G., Saleh M.N., Marcher C. et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393–402.29.29. Kuter D.J., Mufti G.J., Bain B.J., Hasserjian R.P., Davis W., Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009;114:3748–56.Kuter D.J., Mufti G.J., Bain B.J., Hasserjian R.P., Davis W., Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009;114:3748–56.30.30. Kumagai Y., Fujita T., Ozaki M. et al. Pharmacodynamics and Pharmacokinetics of AMG 531, a Thrombopoiesis-Stimulating Peptibody, in Healthy Japanese Subjects: A Randomized, Placebo-Controlled Study. J Clin Pharmacol 2007;47:1489–97.Kumagai Y., Fujita T., Ozaki M. et al. Pharmacodynamics and Pharmacokinetics of AMG 531, a Thrombopoiesis-Stimulating Peptibody, in Healthy Japanese Subjects: A Randomized, Placebo-Controlled Study. J Clin Pharmacol 2007;47:1489–97.31.31. Kuter D., Rummel M., Boccia R. et al. Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. The new England journal of medicine established in 1812 November 11, 2010;363(20):1889–999.Kuter D., Rummel M., Boccia R. et al. Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. The new England journal of medicine established in 1812 November 11, 2010;363(20):1889–999.32.32. Gernsheimer T., Kuter D.J., Cines D.B. et al. Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP) Absracts of 52nd ASH Annual Meeting Orlando, Abstr.3701.Gernsheimer T., Kuter D.J., Cines D.B. et al. Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP) Absracts of 52nd ASH Annual Meeting Orlando, Abstr.3701.33.33. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120(4):574–96.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120(4):574–96.34.34. Blanchette V., Imb ach P., Andrew M., Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344(8924):703–7.Blanchette V., Imb ach P., Andrew M., Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344(8924):703–7.35.35. Newland A.C., Treleaven J.G., Minchinton R.M., Waters A.H. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983 Jan 15;1(8316):84–7.Newland A.C., Treleaven J.G., Minchinton R.M., Waters A.H. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983 Jan 15;1(8316):84–7.36.36. Carroll R.R., Noyes W.D., Rosse W.F., Kitchens C.S. Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. Am J Med 1984 Mar 30;76(3A):181–6.Carroll R.R., Noyes W.D., Rosse W.F., Kitchens C.S. Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. Am J Med 1984 Mar 30;76(3A):181–6.37.37. Janvier M., Clauvel J.P., Tobelem G. Treatment of chronic autoimmune thrombopenic purpura with intravenous immunoglobulins. Study of 18 cases. Nouv Rev Fr Hematol 1983;25(4):253–7.Janvier M., Clauvel J.P., Tobelem G. Treatment of chronic autoimmune thrombopenic purpura with intravenous immunoglobulins. Study of 18 cases. Nouv Rev Fr Hematol 1983;25(4):253–7.38.38. Schiavotto C., Ruggeri M., Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993;78(6 Suppl 2):35–40.Schiavotto C., Ruggeri M., Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993;78(6 Suppl 2):35–40.39.39. Bussel J.B., Psaila B., Saleh M.N. et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [50th ASH Annual Meeting abstract]. Blood 2008;112:3431.Bussel J.B., Psaila B., Saleh M.N. et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [50th ASH Annual Meeting abstract]. Blood 2008;112:3431.40.40. Tarantino M., Bussel J., Saleh M. et al. Eltrombopag helps chronic idiopatic thrombocytopenic purpura patients to undergo procedures without bleeding or additional treatment to rise platelet counts. Hematologica 2008;93(Suppl 1):296.Tarantino M., Bussel J., Saleh M. et al. Eltrombopag helps chronic idiopatic thrombocytopenic purpura patients to undergo procedures without bleeding or additional treatment to rise platelet counts. Hematologica 2008;93(Suppl 1):296.41.41. Najean Y., Rain J-D., Billotey C. et al. The site of destruction of autologous 111 In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. British Journal of Haematology 1997;97(3):547–50.Najean Y., Rain J-D., Billotey C. et al. The site of destruction of autologous 111 In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. British Journal of Haematology 1997;97(3):547–50.42.42. Krauth M., Lechner K., Neugebauer E.A.M. et al. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention — an unresolved issue. Haematologica 2008;9(8):1227–32.Krauth M., Lechner K., Neugebauer E.A.M. et al. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention — an unresolved issue. Haematologica 2008;9(8):1227–32.